{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-001236","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.673771+00:00","generated_at":"2026-06-20T20:18:57.639372+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Acumen appoints Dr. Derrell Porter to board effective Jan. 4, 2023","bullets":["Dr. Porter appointed as Class II independent director; named to Nominating and Governance Committee.","He receives 50,000-share stock option with 10-yr term, vesting monthly over 3 years.","Annual retainer of $35,000 for board service and $4,000 for committee service.","Dr. Porter is Founder/CEO of Cellevolve; brings drug development and commercialization expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-001236","json":"https://secwatch.observer/filing/0001193125-23-001236.json","markdown":"https://secwatch.observer/filing/0001193125-23-001236.md","text":"https://secwatch.observer/filing/0001193125-23-001236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523001236/0001193125-23-001236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523001236/d367027d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:18:57.639372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"138e716d72","claim":"Dr. Derrell Porter was appointed as director at Acumen Pharmaceuticals, Inc..","evidence_excerpt":"On January 3, 2023, the Board of Directors (the “ Board ”) of Acumen Pharmaceuticals, Inc. (the “ Company ”) approved the appointment of Dr. Derrell Porter to serve as a director on the Board, effective January 4, 2023 (the “ Effective Date ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523001236/0001193125-23-001236-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}